KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Non-Current Deffered Revenue (2020 - 2025)

Sarepta Therapeutics has reported Non-Current Deffered Revenue over the past 9 years, most recently at $83.9 million for Q4 2025.

  • Quarterly results put Non-Current Deffered Revenue at $83.9 million for Q4 2025, down 74.18% from a year ago — trailing twelve months through Dec 2025 was $83.9 million (down 74.18% YoY), and the annual figure for FY2025 was $83.9 million, down 74.18%.
  • Non-Current Deffered Revenue for Q4 2025 was $83.9 million at Sarepta Therapeutics, down from $325.0 million in the prior quarter.
  • Over the last five years, Non-Current Deffered Revenue for SRPT hit a ceiling of $641.5 million in Q1 2021 and a floor of $83.9 million in Q4 2025.
  • Median Non-Current Deffered Revenue over the past 5 years was $485.0 million (2022), compared with a mean of $450.4 million.
  • Peak annual rise in Non-Current Deffered Revenue hit 0.0% in 2025, while the deepest fall reached 74.18% in 2025.
  • Sarepta Therapeutics' Non-Current Deffered Revenue stood at $574.2 million in 2021, then dropped by 15.54% to $485.0 million in 2022, then dropped by 9.9% to $437.0 million in 2023, then decreased by 25.63% to $325.0 million in 2024, then plummeted by 74.18% to $83.9 million in 2025.
  • The last three reported values for Non-Current Deffered Revenue were $83.9 million (Q4 2025), $325.0 million (Q1 2025), and $325.0 million (Q4 2024) per Business Quant data.